文献速递血液透析通路

血液透析患者肱动脉转位术的结局

Outcomes of brachial artery transposition in hemodialysis patients.
PubMed 文献 · J Vasc Surg · 2024-05-14

单中心回顾性研究纳入2006年6月1日至2022年12月31日连续193例因不适合建立动静脉内瘘或人工血管而动静脉通路困难、接受肱动脉转位(BAT)作为三级替代通路的血液透析患者,手术成功率93.2%,BAT 10年一期通畅率71.9%、二期通畅率74.9%,全通路5年一期通畅率26.9%、二期通畅率68.6%,作者认为BAT长期通畅性优良、全通路通畅性尚可、并发症少,是不适合常规通路建立者的有效替代选择。

要点

  • BAT手术成功率93.2%,平均手术时间128分钟,术后首次穿刺中位间隔21天。
  • BAT 10年一期通畅率71.9%、二期通畅率74.9%;全通路5年一期通畅率26.9%、二期通畅率68.6%。
  • BAT废弃原因包括肱动脉血栓形成6例、假性动脉瘤2例、动脉瘤样变1例及其他原因1例。

核心结论

  • BAT的通畅性优良,全通路通畅性尚可,并发症较少,从长期角度看是不适合常规血液透析通路建立患者的有效替代选择。

研究设计与样本

  • 单中心回顾性研究,纳入2006年6月1日至2022年12月31日连续接受BAT建立血液透析血管通路的患者,共193例手术。
  • 分别独立评估全通路和转位肱动脉本身的通畅性。

主要发现

  • 手术成功率为93.2%,平均手术时间128分钟,从通路建立到首次穿刺的中位间隔为21天。
  • BAT一期通畅率在1、2、3、5、10年分别为92.3%、91.3%、90.3%、86.1%、71.9%。
  • BAT二期通畅率在1、2、3、5、10年分别为96.3%、96.3%、95.0%、90.1%、74.9%。
  • 全通路一期通畅率在1、2、3、5年分别为61.4%、49.2%、45.8%、26.9%;二期通畅率在1、2、3、5年分别为85.1%、83.3%、82.0%、68.6%。
  • 患者总生存率在1、2、3、5、10年分别为79.6%、69.6%、54.6%、36.5%、13.4%;BAT废弃原因为肱动脉血栓形成(n=6)、假性动脉瘤(n=2)、动脉瘤样变(n=1)及其他原因(n=1)。

临床怎么用

  • 作者认为,对于不适合建立常规血液透析通路的患者,BAT从长期角度看是有效的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In hemodialysis patients with a difficult access extremity who are not suitable for an arteriovenous fistula or arteriovenous graft creation, the concept of cannulating a superficialized artery for arterial outflow in dialysis sessions has been adopted as a tertiary alternative. However, its long-term patency and complications have not been recognized widely. We report our 16-year experience with hemodialysis access creation using the brachial artery transposition (BAT) technique. METHODS: This single-center retrospective study included consecutive patients who underwent BAT for hemodialysis vascular access between June 1, 2006, and December 31, 2022. The patency of the whole access circuit and the transposed brachial artery itself was evaluated independently. RESULTS: In total, 193 surgical procedures were included. The success rate was 93.2%. The mean operative time was 128 minutes. The median interval from access placement to first cannulation was 21 days. The primary patency rates for BAT were 92.3%, 91.3%, 90.3%, 86.1%, and 71.9% at 1, 2, 3, 5, and 10 years, respectively. The secondary patency rates for BAT were 96.3%, 96.3%, 95.0%, 90.1%, and 74.9% at 1, 2, 3, 5, and 10 years, respectively. The primary patency rates for the whole access circuit were 61.4%, 49.2%, 45.8%, and 26.9% at 1, 2, 3, and 5 years, respectively. The secondary patency rates for the whole access circuit were 85.1%, 83.3%, 82.0%, and 68.6% at 1, 2, 3, and 5 years, respectively. The overall patient survival rates were 79.6%, 69.6%, 54.6%, 36.5%, and 13.4% at 1, 2, 3, 5 and 10 years, respectively. The abandonments of BAT were brachial artery thrombosis (n = 6), pseudoaneurysm (n = 2), aneurysmal change (n = 1), and other reasons (n = 1). The abandonments of the whole access circuit were exhaustion of venous return (n = 26), abandonment of BAT (n = 7), and other reasons (n = 2). Complications were exhaustion of venous return (n = 26), aneurysmal change (n = 12), pseudoaneurysm (n = 6), brachial artery thrombosis (n = 7), impaired wound healing (n = 19), lymphorrhea (n = 9), skin infection (n = 5), hematoma on cannulation (n = 3), and reduced peripheral blood flow (n = 2). CONCLUSIONS: The patency of BAT was excellent, and that of the whole access circuit was adequate, with a few complications. BAT is an effective alternative from a long-term perspective for patients who are unsuitable for conventional hemodialysis access creation.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Morita K, Murakami M, Akagi R, et al. Outcomes of brachial artery transposition in hemodialysis patients. J Vasc Surg. 2024. PMID: 38750943. doi:10.1016/j.jvs.2024.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。